Ernie Tremblay- Money Morning - Only the News You Can Profit From.
Once singled out as the "most winning" stock-picker in the investment newsletter industry, Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies.
As a health editor and writer, he has contributed to more than 100 publications on topics like diabetes, Alzheimer's disease, arthritis, dermatology, and groundbreaking medical therapies, for top publishers such as Prentice Hall, Harper Collins, and others. Over the decades, Ernie has gained "insider" access to some of the world's top medical professionals, including Nobel-caliber doctors like Yale's Karel Liem, Columbia's George Gaylord Simpson, and Harvard's William S. Beck.
Ernie understands the FDA approval process, as well as the "hard science" behind new, experimental drugs and the market demand for them - and has a comprehensive grasp of the complex dynamics that determine whether a new drug will be a breakthrough winner, or just another casualty of the FDA approval process.
He puts that knowledge to work for members of his Biotech Insider Alert service, using a proprietary Three-Phase System that identifies the next "blockbuster" drugs and determines whether upcoming regulatory events will make a stock rocket skyward or plunge in the opposite direction . As a consulting editor for Money Map Press since 2012, Ernie's service has given readers opportunities to land substantial gains - including one bioscience stock that generated triple-digit gains four times in eight months.
Ernie'S LATEST HEADLINES
Biotechs 1 Thursday, February 1, 2018The One Thing You Must Know to Hit It Big in Biotech
When you're evaluating a biotech, or even a full-fledged pharmaceutical company, you'll want to look at its product pipeline, upcoming catalysts, and financial indicators.
But the most important asset it possesses, the heartbeat that drives everything else, is its intellectual property (patent) portfolio…
That's what will make it attractive for acquisition, merger, or licensing deals.
And that's what protects its products from marauding generic drug manufacturers, who will produce copycat therapies and sell them at cutthroat prices.
For a drug development company, that spells disaster.When a drug goes generic, it's not unusual for the original brand manufacturer's market share to drop more than 40%...
Biotechs 0 Friday, January 19, 2018Bypass These Pitfalls to (Major) Profits in Bioscience
Biotechs 0 Wednesday, December 13, 2017How to Spot Biotech Shares with "Blockbuster" Potential
Biotechs 0 Thursday, March 16, 2017This "Quick Doubler" Biotech Will Likely Disappoint
Best Profit Opportunities 0 Thursday, March 31, 2016How to Protect Your Biotech Profits from This Legal Limbo
Biotechs 3 Monday, February 1, 2016How to Make a (Consistent) Killing in Biotech Investing in 2016
Biotechs 0 Friday, September 25, 2015What Hillary's Pharma Plan Means for Biotech Investors
Biotechs 9 Thursday, August 20, 2015Two Tactics for Bigger Biotech Investing Profits
Biotechs 7 Friday, August 7, 2015This Bioscience Company Has "Nearly Limitless" Income Potential
Biotechs 2 Friday, June 19, 2015These Promising Cancer Therapies Are a Biotech "Triple Play"